Evidence map›Paper›PMID 34160681›Full record

ArticleWorld journal of urology2021

Perioperative outcomes of transurethral resection for t1 bladder tumors: quality evaluation based on patient, tumor and surgeon criteria.

Sonia Bebane, Justine Denize, Annabelle Goujon, Paul Meria, Jerome Verine, Pierre Mongiat-Artus, Francois Desgrandchamps, Alexandra Masson-Lecomte

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Sonia BebaneService D'Urologie, Hôpital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France.
Justine DenizeService D'Urologie, Hôpital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France.
Annabelle GoujonService D'Urologie, Hôpital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France.
Paul MeriaService D'Urologie, Hôpital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France.
Jerome VerinePathology Department, Saint Louis Hospital, APHP, Paris, France.
Pierre Mongiat-ArtusService D'Urologie, Hôpital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France.
Francois DesgrandchampsService D'Urologie, Hôpital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France.
Alexandra Masson-LecomteService D'Urologie, Hôpital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France. amassonlecomte@gmail.com.ORCID http://orcid.org/0000-0001-8591-3236
Assistance Publique – Hôpitaux de Paris · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTransurethral resection of bladder tumor (TURBT) is a fundamental but challenging step in the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC). The first- and second-look TURBT are central in the management of T1 tumors. MATERIALS AND

methodsWe retrospectively reviewed all patients treated with TURBT for T1 urothelial cell carcinoma (UCC) of the bladder in one academic institution between 2007 and 2017. Quality of TURBT was evaluated based on the presence/absence of muscle on pathology report, the presence/absence of residual tumor on the second look and the occurrence of complications. Patient-, surgeon- and tumor-related factors were investigated for their association with TURBT quality.

results283 patients were included. Second-look resection was performed after a mean delay of 54 days. Muscle was observed in 85.9% of the samples on the first TURBT. On the second-look resection, UCC was observed in 52.3% of the samples. 38 complications were reported after the first TURBT (13.4%). Surgeon's experience was the only factor significantly associated with occurrence of post-operative complications (OR = 0.40; p = 0.04). Location of the tumor at the bottom of the bladder was a risk factor for not finding muscle at pathological analysis (OR = 0.20; p = 0.06). Male gender, multiplicity and tumor located at the bottom of the bladder were significantly associated with residual disease on reTURBT. In multivariate analysis, only male gender (OR = 4.71; p = 0.02) and tumor multiplicity remained significant (OR for unique tumor = 0.36; p = 0.02).

conclusionTURBT is a challenging procedure and surgeon's experience is crucial in reducing the rate of post-operative complications. Technical difficulties resulting from patient's gender, tumor location or number of tumors may be as important as oncological factors in deciding whether or not to perform a second-look resection.

Indexed as

CystectomyAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm, ResidualNeoplasm StagingQuality of Health CareRetrospective StudiesUrethraUrinary Bladder NeoplasmsBladder cancerComplicationsSecond lookTeaching programTURB

Identifiers

PMID34160681
OpenAlexW3174770140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.